Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients After Resection of Liver Cancer
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Biological: cytokine-induced killer cell (CIK) treatment
- Registration Number
- NCT00769106
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
Study hypothesis:
The recurrence rate of HCC patients after radical resection is about 60-70%. This study is based on the hypothesis that CIK treatment could decrease the recurrence rate by 15% to 20%.
Abstract:
This is a randomized controlled study. About 200 patients with hepatocellular carcinoma who underwent radical resection will be included. The patients will be randomized to group A (receive CIK treatment) or group B (just regularly follow up) without any anti-cancer treatment after resection of HCC, and the randomize ratio will be 1:1.
Study treatment:
Patients in group A will receive 4 cycles of CIK treatments within 3 months after their liver resection. Patients in group B will have no anti-cancer therapy. Anti-virus and other supportive therapies are available in both groups.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A (CIK group) cytokine-induced killer cell (CIK) treatment cytokine-induced killer cell treatment plus regular treatment and follow up
- Primary Outcome Measures
Name Time Method Time to recurrence (TTR) month
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) month Laboratory findings every 3 months AEs and SAEs monthly Overall survival (OS) month
Trial Locations
- Locations (1)
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China